Assertio Holdings Inc. has announced the publication of results from a clinical trial investigating same-day dosing of Rolvedon® (eflapegrastim-xnst) injection in patients with early-stage breast cancer undergoing TC chemotherapy (docetaxel and cyclophosphamide). The peer-reviewed results, published in The Oncologist, indicate that same-day administration of Rolvedon demonstrated effective neutrophil recovery and an adverse event profile similar to next-day dosing. The study enrolled 53 patients, with 49 completing the trial, and reported a low incidence of febrile neutropenia and no neutropenic complications. The results have already been published. The benefits of same-day dosing of eflapegrastim-xnst have not been evaluated in a randomized controlled trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assertio Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260109405279) on January 09, 2026, and is solely responsible for the information contained therein.